Marinus Pharmaceuticals Provides Business Update and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2014 Financial Results

RADNOR, Pa., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS ), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today provided a business update and announced its financial results for the third quarter ended September 30, 2014.

"We are pleased with the ganaxolone developments and company accomplishments that occurred in the third quarter which pave the way towards achieving several important milestones for Marinus," commented Christopher M. Cashman, Chairman and CEO of Marinus Pharmaceuticals. "With the successful completion of our initial public offering during the third quarter, we are now funded to deliver on key near term clinical results that we believe to be drivers to unlocking the value within our ganaxolone franchise."

Pipeline Highlights

Ganaxolone in Adult Focal Onset Epileptic Seizures:

Marinus is currently conducting a Phase 3 clinical trial evaluating ganaxolone in adult patients with drug-resistant focal onset epileptic seizures. Marinus is onboarding four new geographies to double the number of study sites, and plans to enroll up to 300 patients in the United States, Australia, Bulgaria, Germany, Poland and Russia. Data from this Phase 3 study are anticipated in the second half of 2015.

Ganaxolone in Orphan Indications –PCDH19 Female Pediatric Epilepsy and Fragile X Syndrome:

Marinus is preparing to initiate a Phase 2 proof-of-concept, open-label clinical trial in up to ten patients with PCDH19 female pediatric epilepsy. PCDH19 is a rare disorder in which a mutation of the PCDH19 gene causes deficits in GABAergic signaling, which are believed to lead to clusters of seizures that can last from one day to weeks that contribute to developmental delay, intellectual disability and behavioral problems. Although formal epidemiologic data is not available, results from diagnostic screenings indicate that approximately 10% of girls who have seizure onset before five years of age have PCDH19 mutations. Marinus anticipates releasing top-line data from the initial tranche of patients in the first half of 2015.

In addition, enrollment is progressing with the ongoing investigator-sponsored Phase 2 proof-of-concept pediatric clinical trial evaluating ganaxolone as a treatment for behaviors in Fragile X Syndrome (FXS). FXS is a genetic condition that causes intellectual disability, anxiety, and behavioral challenges.  Currently, there are no known cures or approved therapies for FXS. Top-line results are anticipated in mid-2015.

Other Formulations of Ganaxolone:

To date, ganaxolone has been administered in over 1,000 patients in oral capsule and suspension dose forms. Marinus is conducting the requisite pre-clinical experiments necessary to ready the intravenous formulation of ganaxolone for human clinical testing. Ganaxolone IV is being developed for the hospital in-patient setting as a compliment to existing oral dose forms for potential use in step-down therapy and for other acute care indications.

Financial Update

Marinus reported net losses of $1.7 million and $7.2 million for the three and nine months ended September 30, 2014, respectively, compared to $1.2 million and $3.9 million for the same periods in the prior year. Cash used in operating activities was $6.6 million for the nine months ended September 30, 2014 compared to $3.5 million for the same period a year ago. 

Research and development expenses increased to $1.6 million and $6.5 million for the three and nine months ended September 30, 2014, respectively, compared to $1.0 million and $3.0 million for the same periods in the prior year. The increases resulted primarily from an increase in clinical costs related to our ongoing clinical trial of ganaxolone in patients with focal onset seizures that commenced at the end of 2013. Substantially all research and development expenses relate to our clinical trial in focal onset epileptic seizures.

General and administrative expenses increased to $0.9 million and $1.8 million for the three and nine months ended September 30, 2014, respectively, compared to $0.3 million and $0.9 million for the same periods in the prior year. The increases in general and administrative expenses were primarily due to the hiring of new management and the upward scaling of our operations in connection with both our new public company status and ongoing clinical trial of ganaxolone in patients with focal onset seizures that commenced during 2013.

At September 30, 2014, the Company had cash and cash equivalents of $47.1 million, compared to $10.0 million at December 31, 2013. The increase was primarily due to $41.2 million in net proceeds received from the sale of 5,758,000 shares of common stock through the initial public offering that the Company completed during the third quarter. The Company believes that its cash and cash equivalents as of September 30, 2014 is adequate to fund operations into 2016.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate, ganaxolone, is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone is known for its anticonvulsive and antianxiety effects, and was designed to avoid hormonal side-effects associated with endogenous neurosteroids. Ganaxolone is presently being studied in a multinational, randomized, placebo-controlled, Phase 3 clinical trial in adult subjects for adjunctive treatment of partial-onset seizures. The Company currently has a Phase 2 proof-of-concept pediatric clinical trial in progress for ganaxolone as a treatment for behaviors in Fragile X Syndrome and is initiating a Phase 2 proof-of-concept clinical study later this year for the treatment of PCDH19 female pediatric epilepsy. Both Fragile X Syndrome and PCDH19 female pediatric epilepsy are potential orphan disorders that have been related to mutations affecting neurosteroid signaling at extrasynaptic GABA A receptors. For additional information, please visit the Company's website at www.marinuspharma.com .

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward looking statements contained in this press release include, among others, statements regarding our expectations regarding our development plans for our product candidate, including optimizing a product's formulation and the clinical trial testing schedule, including clinical trial expansion into new geographic areas and attaining milestones within a particular time frame.  Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of future clinical trials, the timing of the clinical trials, enrollment in clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, and other matters, including the development of formulations of ganaxolone, that could affect the availability or commercial potential of our drug candidates. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.

MARINUS PHARMACEUTICALS, INC.
SELECTED FINANCIAL DATA (unaudited)
         
      September 30, 2014 December 31, 2013
         
ASSETS        
Cash and cash equivalents     $47,105,069 $10,037,123
Other assets     455,809 1,786,822
Total assets     $47,560,878 $11,823,945
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)        
Total current liabilities      1,335,386  2,365,770
Notes payable      2,000,000  — 
Total liabilities      3,335,386  2,365,770
Total stockholders' equity (deficit)      44,225,492  (60,382,031)
Total liabilities and stockholders' equity (deficit)     $47,560,878 $11,823,945
         
  Three Months Ended September 30, Nine Months Ended September 30,
  2014 2013 2014 2013
         
Expenses:        
Research and development $1,568,740 $1,008,469 $6,537,617 $3,020,884
General and administrative  868,301  313,421  1,827,658  869,207
Loss from operations  (2,437,041)  (1,321,890)  (8,365,275)  (3,890,091)
Change in fair value of warrant liability  794,342  91,583  1,191,514  91,583
Interest income  3,794  6,368  6,330  13,856
Interest expense  (29,461)  —   (58,617)  (90,577)
Net loss  (1,668,366)  (1,223,939)  (7,226,048)  (3,875,229)
Cumulative preferred stock dividends  (372,345)  (1,028,837)  (2,545,334)  (2,754,872)
Net loss applicable to common stockholders  $ (2,040,711)  $ (2,252,776)  $ (9,771,382)  $ (6,630,101)
Per share information:        
Net loss per share of common stock—basic and diluted  $ (0.22)  $ (4.58)  $ (2.79)  $ (13.50)
Basic and diluted weighted average shares outstanding 9,449,355 492,319 3,499,808 490,972

Lisa M. Caperelli Senior Director, Investor Relations & Corporate Communications Marinus Pharmaceuticals, Inc. (484) 801-4674

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 85

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Weatherford Adds Grant Roach to Its Sports Deal Team

Updated Category News Views 69

Sports investing has reached that awkward middle age where everybody sees the runway, but few can explain exactly where the bumps are. Weatherford Capital’s decision to bring Grant Roach aboard as vice president is not a headline packed with transaction fireworks. It is, however, a pretty clear tell: the Tampa firm intends to put more bodies and more underwriting muscle...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 68

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Century's Florence Model Openings Put Arizona in Focus

Updated Category News Views 62

Six furnished houses in Florence may sound like a modest ribbon-cutting, but homebuilding is a business of small field signals before the quarterly numbers ever show up. Century Communities is scheduled to host a November grand opening for six model homes spanning two new communities in Florence, Arizona. For investors tracking NYSE:CCS, that is not a thesis by itself. It...

Continue Reading
ActivTrak's Fast 500 Rank Needs Investor Perspective

Updated Category News Views 60

Rank 488 is the sort of trophy that deserves a raised eyebrow, not confetti. ActivTrak made Deloitte's 2026 Technology Fast 500 after posting 101.1% revenue growth from 2022 through 2025, its sixth appearance on the list since 2020. That is real progress, and repeat recognition says this was not a one-quarter sugar high. Still, a Fast 500 ranking is a growth screen, not a...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 137

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 99

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading
Luxor Targets Device Chaos With Kwik IQ Hub Lockers

Updated Category News Views 86

A dead scanner at shift change can make an expensive digital rollout look downright foolish. Luxor Workspaces is aiming squarely at that unglamorous mess with its newly available Kwik IQ Hub smart-locker collection, introduced at the Connected Worker: Manufacturing Summit in Chicago on October 13–15. The pitch is not flashy: put shared radios, scanners, headsets,...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 58

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading
Novo and nference Push Whole-Body Data Into Research

Updated Category News Views 89

Cardiometabolic medicine has spent too long staring at single numbers while the rest of the body keeps waving its arms. Novo Nordisk’s newly announced collaboration with nference is an attempt to widen that lens, combining Novo’s clinical-trial research with nference’s AI technology and federated healthcare data network. The target is not small: obesity, diabetes,...

Continue Reading

Top 5 Most Recently Viewed Articles

OFG Bancorp Reports Stellar Growth in 2024 Financial Results

Updated Category News Views 221

OFG Bancorp's Impressive Financial Results for 2024 OFG Bancorp (NYSE: OFG), the financial holding company for Oriental Bank, has reported robust financial performance for the fourth quarter and full year ended December 31, 2024. This remarkable growth marks an important milestone as the bank continues to enhance its services and strengthen its market positioning. Fourth...

Continue Reading
Innovative Dose Escalation Strategy for Infliximab Therapy

Updated Category News Views 404

Innovative Dose Escalation Strategy for Infliximab Therapy Celltrion, a prominent biopharmaceutical company based in Incheon, South Korea, recently unveiled exciting findings regarding the two-year efficacy of dose escalation therapy with subcutaneous infliximab, known as CT-P13 SC. These results were announced at the United European Gastroenterology (UEG) Week 2024. The...

Continue Reading
Understanding the Impact of Rising Repo Activity on Funding

Updated Category News Views 228

The Rising Repo Activity and Its Implications The recent rise in overnight repurchase agreements, commonly referred to as repos, has significantly influenced the financial landcape. This surge has put immense stress on banks that serve as intermediaries in these transactions, creating potential funding pressures at crucial periods such as quarter-ends and year-ends. What...

Continue Reading
Recent Lawsuit Over Securities at Perpetua Resources Corp. Highlights Shareholder Rights

Updated Category News Views 158

Understanding the Class Action Lawsuit Against Perpetua Resources Corp Levi & Korsinsky, LLP is raising awareness about a class action lawsuit impacting shareholders of Perpetua Resources Corp. This initiative is crucial for investors who experienced losses due to alleged securities fraud associated with the company's operations. Class Definition and Purpose The lawsuit...

Continue Reading
Exciting New Pickleball Kingdom Facility Set for Kentucky

Updated Category News Views 617

Exciting Announcement for Pickleball Enthusiasts Pickleball Kingdom, recognized as the world's largest indoor pickleball organization, is thrilled to announce its latest facility opening in Lexington, Kentucky. With a plan to cover an impressive 42,300 square feet, this state-of-the-art venue will feature 17 professional-grade indoor courts designed to deliver an ultimate...

Continue Reading